Document is current
Any future updates will be listed below
-
Authors
Ivarsson Orrelid, Christoffer
Rosberg, Oscar
Weiner, Sophia
Johansson, Fredrik D.
Gobom, Johan
Zetterberg, Henrik
Mwai, Newton
Stempfle, Lena
-
Funding
Funding for this research was provided by:
Knut och Alice Wallenbergs Stiftelse
Swedish Research Council (#2023-00356; #2022-01018 and #2019-02397)
European Union’s Horizon Europe research and innovation programme (101053962)
Swedish State Support for Clinical Research (ALFGBG-71320)
Alzheimer's Drug Discovery Foundation (201809-2016862)
AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-C)
European Partnership on Metrology, co-financed from the European Union’s Horizon Europe Research and Innovation Programme and by the Participating States (NEuroBioStand, #22HLT07)
Hjärnfonden (FO2022-0270)
European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie (860197 (MIRI ADE))
European Union Joint Programme– Neurodegenerative Disease Research (JPND2021-00694)
National Institute for Health and Care Research Univer sity College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003)
Cure Alzheimer's Fund
Olav Thon Stiftelsen
The Bluefield Project
Erling-Perssons Stiftelse
Familjen Rönströms Stiftelse
Stiftelsen för Gamla Tjänarinnor
Chalmers University of Technology
- License Information
-
More Information
Article History
Received: 29 October 2024
Accepted: 11 February 2025
First Online: 3 March 2025
Declarations
:
: All procedures were approved by the Institutional Review Boards of all participating institutions.
: All authors and co-authors have given their consent for publication.
: Henrik Zetterberg has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, LabCorp, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures sponsored by Alzecure, BioArctic, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, Roche, and WebMD, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work).
